|
시장보고서
상품코드
1421640
레프숨병 치료 시장, 점유율, 규모, 동향, 산업 분석 리포트 : 유형별, 최종사용자별, 연령층별, 지역별, 부문별 예측(2023-2032년)Refsum Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Surgery and Medication); By End User (Hospitals, Clinics, Research Centers, Homecare); By Age Group; By Region; Segment Forecast, 2023 - 2032 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면 세계의 레프숨병 치료 시장 규모는 2032년까지 25억 5,000만 달러에 달할 전망입니다. 이 조사 리포트는 현재의 시장 역학에 관한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
유전성 및 희귀질환과 치료 옵션에 대한 지식과 인식 증가, 전 세계 인구의 급격한 증가, 보다 정확하고 저비용의 새로운 치료 옵션 개발에 대한 정부 지원과 자금 조달 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한 레프숨병의 병태생리에 대한 연구의 확산은 질병에 대한 더 나은 이해와 잠재적인 치료 표적 발굴로 이어질 수 있으며, 다양한 유전자 치료에 대한 정부의 승인 증가와 함께 세계 시장을 적극적으로 촉진할 것으로 보입니다.
예를 들어 2023년 5월 Atsena Therapeutics는 미국 식품의약국(FDA)으로부터 X연쇄 망막 이완증 유전자 치료제의 1/2상 임상시험 개시에 대한 승인을 받았다고 발표했습니다.
유전자 검사 및 분자 프로파일링의 발전은 개인별 맞춤 치료를 가능하게 하고, 개인의 특정 유전적 프로파일과 질병 특성에 맞는 치료법의 보급을 확대하여 보다 효과적이고 표적화된 개입을 가능하게 하고 있으며, 가까운 미래에 새로운 성장의 길과 기회를 열어줄 가능성이 높습니다.
전 세계에서 급증하고 있는 맞춤형 의료 접근법은 기본적으로 유전자 검사 및 분자 프로파일링의 발전으로 환자 개개인프로파일에 맞는 치료 계획을 수립하고, 그 결과 레프섬과 같은 희귀질환을 앓고 있는 환자들에게 보다 효과적인 개입이 이루어질 수 있도록 하는 것입니다. 수 있게 될 것입니다.
시장에 진입하려는 스타트업과 신규 기업의 수가 급증하고 있으며, 환자들에게 보다 효과적이고 효율적인 치료 솔루션을 제공하기 위해 연구개발에 막대한 투자를 하고 있습니다. 또한 기존 치료 기술을 발전시키기 위해 여러 임상시험과 의학 연구를 진행하며 세계 시장에서 입지를 확보하기 위해 노력하고 있습니다.
레프숨병 치료 시장 보고서 하이라이트
- 레프숨병과 같은 희귀질환 환자들 사이에서 효과적인 수술 솔루션에 대한 수요가 증가함에 따라 수술 부문이 주목할 만한 시장 점유율을 차지하고 있습니다.
- 병원에는 첨단 설비와 진단 기술이 잘 갖추어져 있으며, 병원 부문이 큰 비중을 차지하며 업계를 주도하고 있음.
- 주로 전 세계 성인 인구 증가와 다양한 희귀질환을 앓고 있는 사람들 증가에 기인합니다.
- 북미는 잘 구축된 의료 인프라의 존재와 치료 옵션의 가용성에 대한 인식으로 인해 시장을 독점하고 있습니다.
- 주요 시장 기업으로는 Ceuta Healthcare, Illumina, Nurotron Biotechnology, William Demant Holding, Cochlear, BioRad Laboratories 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 레프숨병 치료 시장 인사이트
- 레프숨병 치료 시장 - 최종사용자의 스냅숏
- 레프숨병 치료 시장 역학
- 촉진요인과 기회
- 다양한 희귀 유전성 질환에 관한 우려의 증대
- 의학 조사와 치료법의 진보
- 억제요인과 과제
- 고액의 치료비와 한정된 액세스
- 촉진요인과 기회
- PESTEL 분석
- Refsum 질환 치료 시장 최종사용자 동향
- 밸류체인 분석
- COVID-19 감염증의 영향 분석
제5장 세계의 레프숨병 치료 시장, 유형별
- 주요 조사 결과
- 서론
- 수술
- 약제
제6장 세계의 레프숨병 치료 시장, 연령층별
- 주요 조사 결과
- 서론
- 소아
- 성인
제7장 세계의 레프숨병 치료 시장, 최종사용자별
- 주요 조사 결과
- 서론
- 병원
- 클리닉
- 연구 센터
- 홈케어
제8장 지역의 세계의 레프숨병 치료 시장
- 주요 조사 결과
- 서론
- 레프숨병 치료 시장 평가, 지역별, 2019-2032년
- 레프숨병 치료 시장 - 북미
- 북미 : 레프숨병 치료 시장, 유형별, 2019-2032년
- 북미 : 레프숨병 치료 시장, 최종사용자별, 2019-2032년
- 북미 : 레프숨병 치료 시장, 연령층별, 2019-2032년
- 리후삼 질환 치료 시장 - 미국
- 레프숨병 치료 시장 - 캐나다
- 레프숨병 치료 시장 - 유럽
- 유럽 : 레프숨병 치료 시장, 유형별, 2019-2032년
- 유럽 : 레프숨병 치료 시장, 최종사용자별, 2019-2032년
- 유럽 : 레프숨병 치료 시장, 연령층별, 2019-2032년
- 레프숨병 치료 시장 - 영국
- 레프숨병 치료 시장 - 프랑스
- 레프숨병 치료 시장 - 독일
- 레프숨병 치료 시장 - 이탈리아
- 레프숨병 치료 시장 - 스페인
- 레프숨병 치료 시장 - 네덜란드
- 레프숨병 치료 시장 - 러시아
- 레프숨병 치료 시장 - 아시아태평양
- 아시아태평양 : 레프숨병 치료 시장, 유형별, 2019-2032년
- 아시아태평양 : 레프숨병 치료 시장, 최종사용자별, 2019-2032년
- 아시아태평양 : 레프숨병 치료 시장, 연령층별, 2019-2032년
- 레프숨병 치료 시장 - 중국
- 레프숨병 치료 시장 - 인도
- 레프숨병 치료 시장 - 말레이시아
- 리후삼병 치료 시장 - 일본
- 리후삼병 치료 시장 - 인도네시아
- 레프숨병 치료 시장 - 한국
- 레프숨병 치료 시장 - 중동 및 아프리카
- 중동 및 아프리카 : 레프숨병 치료 시장, 유형별, 2019-2032년
- 중동 및 아프리카 : 레프숨병 치료 시장, 최종사용자별, 2019-2032년
- 중동 및 아프리카 : 레프숨병 치료 시장, 연령층별, 2019-2032년
- 레프숨병 치료 시장 - 사우디아라비아
- 레프숨병 치료 시장 - 아랍에미리트
- 레프숨병 치료 시장 - 이스라엘
- 리후삼병 치료 시장 - 남아프리카
- 레프숨병 치료 시장 - 라틴아메리카
- 라틴아메리카 : 레프숨병 치료 시장, 유형별, 2019-2032년
- 라틴아메리카 : 레프숨병 치료 시장, 최종사용자별, 2019-2032년
- 라틴아메리카 : 레프숨병 치료 시장, 연령층별, 2019-2032년
- 리후삼병 치료 시장 - 멕시코
- 레프숨병 치료 시장 - 브라질
- 레프숨병 치료 시장 - 아르헨티나
제9장 경쟁 구도
- 확장과 인수의 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 개요
- Agilent Technologies
- B. Braun Medical Inc.
- BioRad Laboratories Inc.
- Ceuta Healthcare Limited
- Cochlear Ltd.
- Cook
- Fresenius Kabi
- Igenomix
- Illumina Inc.
- Medline Industries Inc.
- Nurotron Biotechnology Co. Ltd.
- Sequenom
- Sonova
- William Demant Holding A/S
The global refsum disease treatment market size is expected to reach USD 2.55 billion by 2032, according to a new study by Polaris Market Research. The report "Refsum Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Surgery and Medication); By End User (Hospitals, Clinics, Research Centers, Homecare); By Age Group; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Increasing knowledge and awareness about genetic and rare disorders and their available treatment options and the rapid increase in global population, along with the surging government support and rising funding for the development of new and more enhanced treatment options with higher accuracy and low costs, are among the prominent factors driving the market growth. Additionally, the proliferation of research into the pathophysiology of refsum disease that could lead to a better understanding of the condition and the development of potential treatment targets, along with the increase in government approvals for various gene therapies, is likely to foster the global market positively.
For instance, in May 2023, Atsena Therapeutics announced that they had successfully received authorization from the US Food and Drug Administration for the launch of their phase 1/2 clinical trial of X-linked retinoschisis gene therapy.
Growing advances in genetic testing and molecular profiling, which allow for a more personalized approach to treatment and increasing proliferation for tailoring therapies to an individual's specific genetic profile and disease characteristics that can lead to more effective and targeted interventions, are likely to open up new growth avenues and opportunities in the near future.
Surging personalized medicine approaches across the globe, which basically involve tailoring treatment plans to individual patient profiles with advancements in genetic testing and molecular profiling, results in more targeted and effective interventions for patients with rare diseases like refsum.
There has been a surge in the number of startups and new companies trying to enter the market and are investing huge amounts in R&D to ensure more effective & efficient treatment solutions for patients. They are also working on several clinical trials and medical research to provide advancements in existing treatment techniques and, thus, looking to secure their position in the global market.
Refsum Disease Treatment Market Report Highlights
- The surgery segment accounted for noteworthy market share on account of the rising need for effective surgical solutions among patients with rare disorders like refsum
- The hospitals segment led the industry market with a substantial share due to the presence of several advanced equipped and diagnostic techniques in hospitals
- The adults segment will grow at the fastest rate, which is mainly attributed to the growing global adult population and the number of people suffering from different rare diseases
- North America dominated the market on account of the presence of well-established healthcare infrastructure and awareness about the availability of treatment options
- The key market players include Ceuta Healthcare, Illumina, Nurotron Biotechnology, William Demant Holding, Cochlear, & BioRad Laboratories
Polaris Market Research has segmented the refsum disease treatment market report based on type, end user, age group, and region:
Refsum Disease Treatment, Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Surgery
- Medication
Refsum Disease Treatment, End User Outlook (Revenue - USD Billion, 2019 - 2032)
- Hospitals
- Clinics
- Research Centers
- Homecare
Refsum Disease Treatment, Age Group Outlook (Revenue - USD Billion, 2019 - 2032)
- Pediatric
- Adults
Refsum Disease Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Refsum Disease Treatment Market Insights
- 4.1. Refsum Disease Treatment Market - End User Snapshot
- 4.2. Refsum Disease Treatment Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing concerns related to various rare and genetic disorders
- 4.2.1.2. Advancements in medical research and therapeutics
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High treatment costs and limited accessibility
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Refsum Disease Treatment Market End User Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Refsum Disease Treatment Market, by Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 5.3. Surgery
- 5.3.1. Global Refsum Disease Treatment Market, by Surgery, by Region, 2019-2032 (USD Billion)
- 5.4. Medication
- 5.4.1. Global Refsum Disease Treatment Market, by Medication, by Region, 2019-2032 (USD Billion)
6. Global Refsum Disease Treatment Market, by Age Group
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 6.3. Pediatric
- 6.3.1. Global Refsum Disease Treatment Market, by Pediatric, by Region, 2019-2032 (USD Billion)
- 6.4. Adults
- 6.4.1. Global Refsum Disease Treatment Market, by Adults, by Region, 2019-2032 (USD Billion)
7. Global Refsum Disease Treatment Market, by End User
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 7.3. Hospitals
- 7.3.1. Global Refsum Disease Treatment Market, by Hospitals, By Region, 2019-2032 (USD Billion)
- 7.4. Clinics
- 7.4.1. Global Refsum Disease Treatment Market, by Clinics, By Region, 2019-2032 (USD Billion)
- 7.5. Research Centers
- 7.5.1. Global Refsum Disease Treatment Market, by Research Centers, By Region, 2019-2032 (USD Billion)
- 7.6. Homecare
- 7.6.1. Global Refsum Disease Treatment Market, by Homecare, By Region, 2019-2032 (USD Billion)
8. Global Refsum Disease Treatment Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Refsum Disease Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
- 8.3. Refsum Disease Treatment Market - North America
- 8.3.1. North America: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.3.2. North America: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.3.3. North America: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.3.4. Refsum Disease Treatment Market - U.S.
- 8.3.4.1. U.S.: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.3.4.2. U.S.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.3.4.3. U.S.: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.3.5. Refsum Disease Treatment Market - Canada
- 8.3.5.1. Canada: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.3.5.2. Canada.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.3.5.3. Canada: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4. Refsum Disease Treatment Market - Europe
- 8.4.1. Europe: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.2. Europe.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.3. Europe: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.4. Refsum Disease Treatment Market - UK
- 8.4.4.1. UK: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.4.2. UK.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.4.3. UK: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.5. Refsum Disease Treatment Market - France
- 8.4.5.1. France: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.5.2. France.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.5.3. France: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.6. Refsum Disease Treatment Market - Germany
- 8.4.6.1. Germany: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.6.2. Germany.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.6.3. Germany: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.7. Refsum Disease Treatment Market - Italy
- 8.4.7.1. Italy: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.7.2. Italy.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.7.3. Italy: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.8. Refsum Disease Treatment Market - Spain
- 8.4.8.1. Spain: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.8.2. Spain.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.8.3. Spain: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.9. Refsum Disease Treatment Market - Netherlands
- 8.4.9.1. Netherlands: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.9.2. Netherlands.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.9.3. Netherlands: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.4.10. Refsum Disease Treatment Market - Russia
- 8.4.10.1. Russia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.4.10.2. Russia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.4.10.3. Russia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5. Refsum Disease Treatment Market - Asia Pacific
- 8.5.1. Asia Pacific: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.2. Asia Pacific.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.3. Asia Pacific: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5.4. Refsum Disease Treatment Market - China
- 8.5.4.1. China: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.4.2. China.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.4.3. China: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5.5. Refsum Disease Treatment Market - India
- 8.5.5.1. India: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.5.2. India.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.5.3. India: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5.6. Refsum Disease Treatment Market - Malaysia
- 8.5.6.1. Malaysia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.6.2. Malaysia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.6.3. Malaysia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5.7. Refsum Disease Treatment Market - Japan
- 8.5.7.1. Japan: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.7.2. Japan.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.7.3. Japan: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5.8. Refsum Disease Treatment Market - Indonesia
- 8.5.8.1. Indonesia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.8.2. Indonesia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.8.3. Indonesia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.5.9. Refsum Disease Treatment Market - South Korea
- 8.5.9.1. South Korea: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.5.9.2. South Korea.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.5.9.3. South Korea: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.6. Refsum Disease Treatment Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.2. Middle East & Africa.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.6.3. Middle East & Africa: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.6.4. Refsum Disease Treatment Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.4.2. Saudi Arabia.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.6.4.3. Saudi Arabia: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.6.5. Refsum Disease Treatment Market - UAE
- 8.6.5.1. UAE: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.5.2. UAE.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.6.5.3. UAE: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.6.6. Refsum Disease Treatment Market - Israel
- 8.6.6.1. Israel: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.6.2. Israel.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.6.6.3. Israel: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.6.7. Refsum Disease Treatment Market - South Africa
- 8.6.7.1. South Africa: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.6.7.2. South Africa.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.6.7.3. South Africa: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.7. Refsum Disease Treatment Market - Latin America
- 8.7.1. Latin America: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.2. Latin America.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.7.3. Latin America: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.7.4. Refsum Disease Treatment Market - Mexico
- 8.7.4.1. Mexico: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.4.2. Mexico.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.7.4.3. Mexico: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.7.5. Refsum Disease Treatment Market - Brazil
- 8.7.5.1. Brazil: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.5.2. Brazil.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.7.5.3. Brazil: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
- 8.7.6. Refsum Disease Treatment Market - Argentina
- 8.7.6.1. Argentina: Refsum Disease Treatment Market, by Type, 2019-2032 (USD Billion)
- 8.7.6.2. Argentina.: Refsum Disease Treatment Market, by End User, 2019-2032 (USD Billion)
- 8.7.6.3. Argentina: Refsum Disease Treatment Market, by Age Group, 2019-2032 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Agilent Technologies
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. B. Braun Medical Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. BioRad Laboratories Inc.
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Ceuta Healthcare Limited
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Cochlear Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Cook
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Fresenius Kabi
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Igenomix
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Illumina Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Medline Industries Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
- 10.11. Nurotron Biotechnology Co. Ltd.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development
- 10.12. Sequenom
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Product Benchmarking
- 10.12.4. Recent Development
- 10.13. Sonova
- 10.13.1. Company Overview
- 10.13.2. Financial Performance
- 10.13.3. Product Benchmarking
- 10.13.4. Recent Development
- 10.14. William Demant Holding A/S
- 10.14.1. Company Overview
- 10.14.2. Financial Performance
- 10.14.3. Product Benchmarking
- 10.14.4. Recent Development
비교리스트